Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.41 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.41 |
| ▸ | TRPV1 | Q8NER1 | 8/20 | 0.41 |
| ▸ | JAK2 | O60674 | 7/20 | 0.38 |
| ▸ | JAK1 | P23458 | 7/20 | 0.38 |
| ▸ | CTSS | P25774 | 1/20 | 0.36 |
| ▸ | SMO | Q99835 | 1/20 | 0.35 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL784714 | 0.94 | TRPV1 (0.42) | TAS1R3TAS1R1TRPV1JAK2JAK1 | |
| SCHEMBL784689 | 0.92 | F10 (0.39) | TRPV1PRMT3 | |
| SCHEMBL785321 | 0.92 | F10 (0.39) | TRPV1PRMT3 | |
| SCHEMBL785714 | 0.92 | TRPV1 (0.38) | TRPV1JAK2JAK1CTSSPRMT3 | |
| SCHEMBL784402 | 0.90 | CTSS (0.40) | TAS1R3TAS1R1JAK2JAK1CTSS | |
| SCHEMBL784019 | 0.90 | TRPV1 (0.40) | TRPV1 | |
| SCHEMBL785529 | 0.88 | TRPV1 (0.40) | TRPV1JAK2JAK1CTSSPRMT3 | |
| SCHEMBL785440 | 0.87 | CTSS (0.38) | TAS1R3TAS1R1JAK2JAK1CTSS | |
| SCHEMBL785937 | 0.87 | TRPV1 (0.40) | TRPV1CTSSPRMT3 | |
| SCHEMBL785530 | 0.87 | JAK2 (0.37) | JAK2JAK1CTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8680159-B2 | Bradykinin 1 receptor modulating compounds | GRUENENTHAL GMBH (DE) | 2014-03-25 | — | — | US | claimed |
| US-20120071461-A1 | Substituted Benzamide Compounds | GRUENENTHAL GMBH (DE) | 2012-03-22 | — | — | US | claimed |
| US-20120071461-A1 | Substituted Benzamide Compounds | GRUENENTHAL GMBH (DE) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071461-A1 | Substituted Benzamide Compounds | BDKRB1, BDKRB2, HRH2 | TAS1R3 202/4885TAS1R1 75/4885TRPV1 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.